Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

c-LEcta GmbH. (12/13/18). "Press Release: Successful Transformation into a Product Company in 2018 with a Promising Outlook for 2019".

Organisations Organisation c-LEcta GmbH
  Organisation 2 Capricorn Venture Partners N.V.
  Group Capricorn Venture Partners (Group)
Products Product industrial biotechnology
  Product 2 Denarase®
  Index term 2 c-LEcta–SEVERAL: investment, 201808 financing round €na with new investors Capricorn Venture Partners + bm|t
Persons Person Struhalla, Marc (c-LEcta GmbH 201105 Managing Director)
  Person 2 Pfaadt, Thomas (c-LEcta 201808– CFO)

c-LEcta continued its successful development towards becoming a product company in fiscal year 2018. Successful products marketed by c-LEcta itself such as DENARASE® contributed to this development. The company also actively advanced the expansion of its corporate structures to support its current growth course and successfully exploit future market potentials.

For c-LEcta, the end of fiscal year 2018 has been marked by successful transformation. The company is going through a development process from a project company into a product company to better exploit existing market potentials in the food and pharmaceutical industries, and to continue its strong growth. Project business activities as a service business in contract research were completely discontinued last year on strategic grounds. This step was taken in order to place an even stronger focus on marketing products developed independently or in strategic cooperation with industry. Product sales and license income are expected to grow in the upper double-digit percentage range in 2018 compared to 2017.

Two of c-LEcta’s products are expected to account for nearly 80% of total product sales: DENARASE® enables highly efficient production processes for biopharmaceuticals. c-LEcta’s sales of this product nearly tripled year-on-year. The company intends to further exploit the market potential of DENARASE® in the double-digit million-euro range by intensifying its sales efforts in 2019. Considerable sales are also expected in the coming year with a process that will contribute to the more efficient production of cancer medications for a large pharmaceutical company. Probably the greatest product success in 2018 was the introduction of a new process to expand the production of plant-based sweeteners with a sugar-like taste. c-LEcta has thus enabled new concepts for sugar reduction, approaching a multibillion-euro market as a technology leader in enzyme engineering. Driven by the trend toward a conscious and healthy diet, c-LEcta’s unique, cost-efficient process and the products it produces are increasingly in demand. This was most recently reflected in the largest order in company history for this process, which produces a vegetable sugar substitute product.

c-LEcta has flanked its transformation into a product-oriented company with structural and organizational investments. It launched projects to digitalize the company’s infrastructure. c-LEcta continued developing its current digital solutions for ordering, shipping and logistical processes. Processes in the HR department and sales are now also to be made more efficient. This will lay the groundwork for continued personnel expansion: the c-LEcta team now has more than 60 employees and has grown by 20% since the beginning of the year. Sales, business development, production and quality management accounted for the lion’s share. c-LEcta also expanded its first management level: Thomas Pfaadt was named CFO in the middle of the year, bringing his extensive experience in corporate finance, M&A and investor relations to the company. The number of employees is expected to continue rising in 2019 to support the intensive expansion of the product and license businesses at all levels. The warehouse, laboratory and office space have also been expanded by a third to meet the needs of the company’s growth strategy.

The company has also been joined by Capricorn and bm|t, two new investors bringing access to further growth capital and an international network. Dr. Marc Struhalla, CEO of c-LEcta, is satisfied: “We achieved a lot in 2018 and were able, thanks in part to the successful financing round, to continue advancing our growth strategy towards becoming a product company. We have many interesting projects in our program for 2019. Our activities in the coming year will focus on the successful commercialization of finished product developments and the expansion and development of our pipeline. I think our work over the last 12 months has set the course for a successful 2019.”

Record changed: 2018-12-19


Picture [LSUS] – The Business Web Portal 650x112px

More documents for c-LEcta GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BioPharm America 2019 Boston September 600x60px

» top